TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18987553
Drug: Buspirone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (20 mg)
Study: 6130065
Drug: Clorazepate (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate (24 mg)
Study: 31891449
Drug: roxadustat (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxadustat (initial dose, 50 or 70 mg) for 24 weeks (ESA-Naïve Study)
Study: 31891449
Drug: roxadustat (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxadustat (initial dose, 70 or 100 mg based on prior ESA dose) for 52 weeks (ESA-Converted Study)
Study: 27975236
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 at 10,000 IU daily
Study: 27975236
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D3 at 1000 IU daily
Study: 27975236
Drug: Both high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high-dose and low-dose vitamin D3
Study: 24400643
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group receiving a half-day training in heart failure management and structured up-titration scheme.
Study: 19219569
Drug: HHH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHH therapy administered over 3-9 days
Study: 17283283
Drug: Flumazenil (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.9 mg intravenous bolus followed by 0.0102 mg/min infusion)
Study: 11680670
Drug: Omeprazole MUPS
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole MUPS 20 mg tablet (Test)
Study: 11680670
Drug: Omeprazole MUPS
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole MUPS 20 mg tablet (Reference)
Study: 11680670
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (Test and Reference)
Study: 27913872
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day of fish oil (2.4 g n-3 PUFA)
Study: 25765839
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of Erigerontis hydroxybenzenes injection (EHI)
Study: 25765839
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of EHI
Study: 19756742
Drug: Doxycycline treatment
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline treatment for 6 weeks
Study: 7835264
Drug: Intraumbilical infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraumbilical infusion through a mucus aspiration catheter
Study: 7835264
Drug: Intraumbilical infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraumbilical infusion by an 18 gauge needle (direct injection)
Study: 26973347
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rivaroxaban OD for 45 days
Study: 26973347
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg fondaparinux OD for 45 days
Study: 15753273
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (0.6 mg/kg, max 10 mg)
Study: 12531351
Drug: Outer membrane
Normalized name: Outer membrane protein 3B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outer membrane vesicle (OMV) vaccines
Study: 3565812
Drug: Neostigmine (0.005,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.005, 0.01, 0.02 or 0.05 mg/kg)
Study: 3565812
Drug: Pyridostigmine (0.02,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (0.02, 0.04, 0.1, or 0.2 mg/kg)
Study: 3565812
Drug: Edrophonium (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.1, 0.2, 0.4 or 1 mg/kg)
Study: 31273506
Drug: Hyaluronan formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan formulation (study cream, S)
Study: 31273506
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream (placebo, P)
Study: 22796108
Drug: Modafinil, 200
Normalized name: Modafinil, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil, 200 mg, once daily
Study: 22796108
Drug: Escitalopram, 20
Normalized name: Escitalopram, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, 20 mg, once daily
Study: 22796108
Drug: Modafinil +
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil + Escitalopram, once daily
Study: 16798442
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with intermittent 10‐mL boluses of 0.125% levobupivacaine into the epidural space and physiologic saline into the surgical wound
Study: 16798442
Drug: Incisional analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional analgesia with intermittent 10‐mL boluses of 0.25% levobupivacaine into the wound and epidural saline
Study: 10762286
Drug: Quinagolide (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinagolide (0.075 to 0.6 mg/day)
Study: 10762286
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 to 3 mg/week)
Study: 26716357
Drug: Controlled-inhalation nebulizer
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-inhalation nebulizer (AKITA)
Study: 22759069
Drug: RIT (regenerative
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT (regenerative injection therapy)
Study: 22759069
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy only
Study: 22759069
Drug: RIT after
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT after exercise therapy
Study: 18482589
Drug: G-FOBT (Hemoccult-II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-FOBT (Hemoccult-II)
Study: 16518579
Drug: Prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (10 mg/day)
Study: 16518579
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/day) and Prednisolone (10 mg/day)
Study: 12901730
Drug: Oral nicorandil-induced
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicorandil-induced lesions
Study: 11180878
Drug: 6.9% branched
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.9% branched chain amino acid (BCAA) solution
Study: 29899395
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy with cisplatin (50 mg/m2) and etoposide (100 mg/m2) followed by intravenous chemotherapy
Study: 29899395
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy alone
Study: 29899395
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy with cisplatin and etoposide
Study: 18237663
Drug: Intravenous catheter
Normalized name: intravenous catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous catheter collection technique
Study: 16247245
Drug: Deep Relief
Normalized name: SALICYLIC ACID 2 g in 100 mL TOPICAL SOLUTION [Deep Relief Acne (Blemish) Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Relief gel (3% menthol)
Study: 16247245
Drug: Ibuleve gel
Normalized name: Ibuleve
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuleve gel (only ibuprofen)
Study: 11885181
Drug: HA-coated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-coated implants
Study: 11885174
Drug: Non-HA implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HA implants
Study: 11885174
Drug: HA-grooved implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-grooved implant
Study: 8599319
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg beta-carotene supplementation
Study: 1568865
Drug: Inhaled ketanserin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ketanserin, 10 mg given 30 min before test
Study: 27631883
Drug: Percent time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percent time with NT-proBNP ≥1000 pg/mL (serial measurement)
Study: 25624376
Drug: Oropharyngeal colostrum
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal colostrum administration (0.2 mL every 3 hours for 3 days)
Study: 20049961
Drug: Oral rapamycin
Normalized name: kanamycin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rapamycin (2 mg/day for 30 days)
Study: 18509181
Drug: Fluorouracil, irinotecan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil, irinotecan, and oxaliplatin (first-line combination chemotherapy)
Study: 14520110
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate (FP, Flonase)
Study: 1441867
Drug: Thiopentone 5‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 5‐6 mg/kg
Study: 1441867
Drug: Propofol 2‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2‐3 mg/kg
Study: 23757968
Drug: Tadalafil combined
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil combined with behavior therapy
Study: 16714425
Drug: 160/12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160/12.5 mg valsartan/hydrochlorothiazide (HCTZ)
Study: 18227782
Drug: Interpersonal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal and social rhythm therapy
Study: 11256459
Drug: Psychoeducation, group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation, group therapy, couples therapy, family therapy, interpersonal psychotherapy
Study: 7943089
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (10 mg, 10 mg, 5 mg, 5 mg) administered in four doses at 12-hour intervals over 36 hours
Study: 2975609
Drug: Celiprolol 200-600
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200-600 mg daily
Study: 2975609
Drug: Chlorthalidone 12.5-37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5-37.5 mg daily
Study: 28286289
Drug: 8mg intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg intravenous zolpidem
Study: 18518938
Drug: Levamisole group
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole group (100 mg levamisole p.o. after each haemodialysis session)
Study: 16598663
Drug: Men with
Normalized name: Peptamen with Prebio Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men with offences against biological daughters or stepdaughters
Study: 10890312
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lithium carbonate for 10 days and 30 mg mirtazapine on day 9
Study: 10890312
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules and 30 mg mirtazapine on day 9
Study: 10890312
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirtazapine and lithium
Study: 1383416
Drug: recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant interferon treatment
Study: 31211741
Drug: Anastrozole or
Normalized name: anastrozole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole or exemestane (5 years of adjuvant therapy)
Study: 30112584
Drug: Interventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional care (up-titrated antihypertensive therapy with a single pill combination of olmesartan, amlodipine, and/or hydrochlorothiazide in 4-week intervals)
Study: 30112584
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (treatment according to the 2013 European Society of Cardiology guidelines)
Study: 8629744
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus diclofenac (150 mg)
Study: 8629744
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus diclofenac (150 mg)
Study: 2899107
Drug: Alcoholic preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic preparations (n-propanol and isopropanol)
Study: 2899107
Drug: Povidone-iodine detergent
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine detergent preparations
Study: 2899107
Drug: Alcoholic formulations
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic formulations
Study: 26876066
Drug: ICG-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-guided therapy (HD)
Study: 26876066
Drug: Empiric therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric therapy (GE)
Study: 22399096
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of 50 mg losartan and 12.5 mg HCTZ (n=109)
Study: 22399096
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with 100 mg losartan (n=107)
Study: 16188740
Drug: Positive expiratory
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive expiratory pressure (PEP) treatment
Study: 16188740
Drug: PEP treatment
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEP treatment (repeated tests)
Study: 12462872
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (Nd:YAG-laser with water spray)
Study: 10497848
Drug: BHAC-DM (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHAC-DM (daunorubicin 40 mg/m2/day x 4 or more, behenoyl cytarabine 200 mg/m2/day x 10 or more, 6-mercaptopurine 70 mg/m2/day x 10 or more)
Study: 10497848
Drug: BHAC-EDM (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHAC-EDM (daunorubicin 40 mg/m2/day x 4 or more, behenoyl cytarabine 200 mg/m2/day x 10 or more, 6-mercaptopurine 70 mg/m2/day x 10 or more, etoposide 100 mg/m2/day x 5)
Study: 8756388
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy after the fifth chemotherapy cycle
Study: 2006875
Drug: Piritrexim 50
Normalized name: Piritrexim
DrugBank: Piritrexim (DB03695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritrexim 50 mg or more twice daily
Study: 2006875
Drug: Piritrexim (dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritrexim (dosages ranged from 25 to 100 mg twice a day)
Study: 31021880
Drug: Carbohydrate-rich drink
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich drink (200 ml) 2 to 3 hours before surgery
Study: 24443305
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg piracetam
Study: 20665424
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation at nutritional doses
Study: 17052819
Drug: Recombinant NspA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant NspA vaccine (rNspA)
Study: 17052819
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available quadravalent meningococcal polysaccharide vaccine (Menomune)
Study: 11814097
Drug: PMX-F treatment
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMX-F treatment (n=7)
Study: 11814097
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n=7)
Study: 2707929
Drug: Nesosteine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesosteine (900 mg/day)
Study: 782135
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate (Becotide) 300 mug/day
Study: 23062791
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) - flexible morning dose (30, 50, 70 mg/day)
Study: 19288980
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk (CM) desensitization protocol, starting with one drop of whole CM diluted 1:25, doubled weekly for 18 weeks to achieve 200 mL intake.
Study: 16817084
Drug: Levobupivacaine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (7 ml of 5 mg/ml)
Study: 16817084
Drug: Control (physiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (physiologic saline solution)
Study: 12629559
Drug: Twice-weekly supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly supervised strength training for 15 weeks followed by 6 months of unsupervised training
Study: 12473477
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 g)
Study: 8491103
Drug: Drugs that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs that modulate sleep, such as tricyclic antidepressants
Study: 8491103
Drug: Other agents
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other agents affecting central nervous system neurotransmitters, particularly serotonin
Study: 10848657
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg b.d.
Study: 21828378
Drug: Cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 20 mg plus mFOLFOX6
Study: 21828378
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg plus mFOLFOX6
Study: 15017668
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy without susceptibility testing
Study: 1579267
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of folate daily around the time of conception
Study: 2870808
Drug: Acetaminophen (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (650 mg) and Pentazocine (25 mg)
Study: 2870808
Drug: Acetaminophen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (300 mg) and Codeine (30 mg)
Study: 2870808
Drug: Acetaminophen (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (650 mg) and Propoxyphene Napsylate (100 mg)
Study: 3784917
Drug: High-dose oestrogen-progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oestrogen-progestogen therapy
Study: 3784917
Drug: Combined oestrogen-progestogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oestrogen-progestogen therapy (all doses)
Study: 3784917
Drug: All treated
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treated groups (including high-dose)
Study: 3784917
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in daily creatinine excretion
Study: 28237253
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of hyaluronic acid (HA)
Study: 26247661
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (150 μg/day)
Study: 21110180
Drug: Aidi Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aidi Injection (ADI) 100 mL added to 500 mL of 5% glucose injection, administered intravenously once daily for 14 days before each course of chemotherapy (total 28 days).
Study: 11001887
Drug: 5‐aza‐2'‐deoxycytidine (5‐aza‐CdR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐aza‐2'‐deoxycytidine (5‐aza‐CdR, decitabine) at doses ranging from 0.15 to 0.30 mg/kg given 5 days a week for 2 weeks
Study: 8482458
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa treatment
Study: 24918560
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate (BT) 0.5% gel
Study: 18261195
Drug: Aripiprazole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 2.5 mg
Study: 15721800
Drug: Cortisol administered
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol administered before recall testing
Study: 12641876
Drug: Treatment recommendations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment recommendations based on evidence from CKD populations or general population
Study: 11006055
Drug: Soymilk supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soymilk supplementation (400 mL daily for two menstrual cycles)
Study: 8784280
Drug: Eutectic lidocaine/prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic lidocaine/prilocaine 5% cream under occlusive dressing (Tegaderm)
Study: 8784280
Drug: Eutectic lidocaine/prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic lidocaine/prilocaine 5% patch
Study: 1732427
Drug: Cisplatin (CP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CP) 100 mg/m2 and Fluorouracil (5-FU) 1 g/m2 x 4
Study: 1732427
Drug: Cisplatin (CP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CP) and Fluorouracil (5-FU) combination
Study: 6365809
Drug: sfericase (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: sfericase (6 tablets/day)